Humanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma
Open Access
- 16 February 2026
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (35) , e19746
Abstract
Major challenges of developing CAR‑T cell therapy for head and neck squamous cell carcinoma (HNSCC) include identifying a robust tumor antigen and a suitable CAR design. Here, we validate chondroitin sulfate proteoglycan 4 (CSPG4) as a highly expressed, prognostic antigen in HPV‑negative HNSCC that drives tumor proliferation. By grafting the murine single‐chain variable fragment (scFv) 763.74 complementarity determining regions (CDRs) onto a human antibody framework engineered to minimize surface positive‑charge patches and immunogenic epitopes, we generated humanized CSPG4 (CSPG4 Hu ) CAR‑T cells with reduced tonic signaling and alleviated exhaustion. Transcriptomic and metabolic profiling reveal that this biophysical refinement reprograms CAR‐T cells away from a glycolytic, terminal exhaustion state toward a PI3K/Akt‐driven stem‐like state. Consequently, CSPG4 Hu CAR‐T cells demonstrate superior persistence and potent antitumor efficacy across systemic xenograft and patient‐derived xenograft models. Our study establishes a rational engineering framework that links biophysical CAR design to transcriptomic and metabolic rejuvenation, offering a promising therapeutic candidate for advanced HNSCC.Keywords
Funding Information
- Shanghai Rising-Star Program (23QA1400900)
- National Natural Science Foundation of China (82471150)
- National Natural Science Foundation of China (82102863)
- National Natural Science Foundation of China (82473310)
- National Natural Science Foundation of China (82271149)
- National Natural Science Foundation of China (81870710)
This publication has 85 references indexed in Scilit:
- Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogrammingCell Metabolism, 2025
- Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck CancerJAMA Oncology, 2025
- Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem CellsAdvanced Science, 2025
- Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancerAnnals of Oncology, 2024
- Immunotherapy for HPV negative head and neck squamous cell carcinomaBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- IGSF8 is an innate immune checkpoint and cancer immunotherapy targetCell, 2024
- The B7:CD28 family and friends: Unraveling coinhibitory interactionsImmunity, 2024
- Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patientsInternational Journal of Cancer, 2014
- Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspectiveElectrophoresis, 2009
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004